MYD88 and B-cell non-Hodgkin lymphoma: Of importance, oncogenically active MYD88 mutations have recently been identified as recurrent genetic lesions in chronic lymphocytic leukemia (CLL), B-cell lymphoma and Waldenström’s macroglobulinemia [10]–[12].